Clinical research into the management of atrial fibrillation—the most common serious arrhythmia—has mostly focused on arrhythmia prevention and the reduction of vascular events and death. In 2010, important advances have been made in stroke prevention with new anticoagulants and in atrial fibrillation rhythm management.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
ClinicalTrials.gov. Randomized evaluation of long term anticoagulant therapy (RE-LY) with dabigatran etexilate [online], (2010).
Wallentin, L. et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalized ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet 376, 975–983 (2010).
Van Gelder, I. C. et al. Lenient versus strict rate control in patients with atrial fibrillation. N. Engl. J. Med. 362, 1363–1373 (2010).
Camm, A. J. et al. Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur. Heart J. 31, 2369–2429 (2010).
Canadian Cardiovascular Society. 2010 Atrial Fibrillation Guidelines [online], (2010).
Hohnloser, S. H. et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N. Engl. J. Med. 360, 668–678 (2009).
Eikelboom, J. W. et al. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K. Am. Heart J. 159, 348–353 (2010).
Becker, R. et al. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF study. Am. Heart J. 159, 340–347 (2010).
Lopes, R. D. et al. Apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial: design and rationale. Am. Heart J. 159, 331–339 (2010).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
S. J. Connolly is a consultant for Bayer and is a consultant and receives grant/research support from Boehringer–Ingelheim, Bristol–Myers Squibb, Portola and Sanofi Aventis.
Rights and permissions
About this article
Cite this article
Connolly, S. Advances in treatment and management. Nat Rev Cardiol 8, 67–68 (2011). https://doi.org/10.1038/nrcardio.2010.206
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrcardio.2010.206
This article is cited by
-
Analysis of QRS-T subtraction in unipolar atrial fibrillation electrograms
Medical & Biological Engineering & Computing (2013)
-
Blood coagulation factor XII—a neglected player in stroke pathophysiology
Journal of Molecular Medicine (2012)
